Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Industry Watch.
Press releases published on April 15, 2025
Bluejay Announces Abstract Accepted for Presentation at the 2025 Society of Academic Emergency Medicine (SAEM) Annual Meeting
GlobeNewswire
·
April 15, 2025
ACTON, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX), today announced acceptance of an abstract related to the Symphony IL-6 Test, the company’s lead product candidate, for presentation at the Society of Academic …
Remix Therapeutics Appoints Linda C. Bain to Board of Directors
GlobeNewswire
·
April 15, 2025
WATERTOWN, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced the …
Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting
GlobeNewswire
·
April 15, 2025
Company to share new preclinical combination data for FHD-909 (LY4050784), a potential first-in-class selective SMARCA2 inhibitor, with non-small cell lung cancer (NSCLC) as the primary target population Additional updates include new preclinical data for …
Conavi Medical Corp. Announces Pricing of Public Offering of Common Shares
GlobeNewswire
·
April 15, 2025
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES A&R PROSPECTUS AND FINAL PROSPECTUS ACCESSIBLE ON SEDAR+ TORONTO, April 15, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI; OTC: CNVIF) (“Conavi” or the “ …
Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model
GlobeNewswire
·
April 15, 2025
Nimacimab shows comparable weight loss to monlunabant and tirzepatide alone, and an additive effect in combination with tirzepatide, in diet-induced obesity model New in vitro data demonstrates superior potency of nimacimab’s differentiated and favorable …
Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit
GlobeNewswire
·
April 15, 2025
HUNTSVILLE, AL, April 15, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Randall Moreadith, M. …
Native Path Native Hydrate Reviews [Urgent Update]: Don’t Buy Until You Read This
GlobeNewswire
·
April 15, 2025
Native Hydrate by Native Path Reviews Woodhaven, N.Y., April 15, 2025 (GLOBE NEWSWIRE) -- What if the key to better hydration and muscle recovery wasn’t in sugary sports drinks but in a clean, science-backed formula? Native Hydrate by Native Path is …
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025
GlobeNewswire
·
April 15, 2025
Company Announcement Net sales of DARZALEX® in the first quarter of 2025 totaled USD 3,237 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; April 15, 2025 – …
Verona Pharma to Report First Quarter 2025 Financial Results and Provide Corporate Update
GlobeNewswire
·
April 15, 2025
LONDON and RALEIGH, N.C., April 15, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday, April 29, 2025 and …
Medāna Enters the Spanish Market with an AI Platform to Transform Healthcare Across Europe
GlobeNewswire
·
April 15, 2025
LISBON, Portugal, April 15, 2025 (GLOBE NEWSWIRE) -- Spain is about to welcome one of the most disruptive technologies in digital health. Medāna (www.medana.ai), the global startup founded by Dr. Tal Patalon , has announced its strategic entry into the …
MEDĀNA ENTRA EN EL MERCADO ESPAÑOL CON UNA PLATAFORMA DE IA PARA TRANSFORMAR LA SANIDAD EN TODA EUROPA
GlobeNewswire
·
April 15, 2025
LISBOA, Portugal, April 15, 2025 (GLOBE NEWSWIRE) -- España está a punto de recibir una de las tecnologías más disruptivas en salud digital. Medāna (www.medana.ai), startup internacional fundada por la Dra. Tal Patalon, ha anunciado su entrada estratégica …
Medāna Enters the Netherlands Market with an AI Platform to Transform Healthcare Across Europe
GlobeNewswire
·
April 15, 2025
LISBON, Portugal, April 15, 2025 (GLOBE NEWSWIRE) -- Netherlands is about to welcome one of the most disruptive technologies in digital health. Medāna (www.medana.ai), the global startup founded by Dr. Tal Patalon, has announced its strategic entry into …
MEDĀNA BETREEDT DE NEDERLANDSE MARKT MET EEN AI-PLATFORM OM DE GEZONDHEIDSZORG TE TRANSFORMEREN IN EUROPA
GlobeNewswire
·
April 15, 2025
LISSABON, Portugal, April 15, 2025 (GLOBE NEWSWIRE) -- Nederland staat op het punt een van de meest baanbrekende technologieën in de digitale gezondheidszorg te verwelkomen. Medāna (www.medana.ai), de startup opgericht door Dr. Tal Patalon, heeft zijn …
Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar
GlobeNewswire
·
April 15, 2025
MILAN and NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- Pierluigi Paracchi, CEO Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, will present at “Montalcini Global Biotech Tour” in Doha, Qatar on April …
HepaRegeniX completes €21.5 million financing to support clinical advancement of HRX-215 for liver regeneration
GlobeNewswire
·
April 15, 2025
Tuebingen, Germany, April 15, 2025 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage company advancing novel therapies to treat acute and chronic liver diseases, today announced the second closing and completion of a €21.5 million financing round with …
Oculis Hosts R&D Event Today to Showcase Progress on All Three Pipeline Assets
GlobeNewswire
·
April 15, 2025
ZUG, Switzerland, April 15, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant …
Concept Life Sciences expands expertise with key appointments to Scientific Advisory Board and investments to strengthen integrated drug discovery capabilities
GlobeNewswire
·
April 15, 2025
CHAPEL-EN-LE-FRITH, United Kingdom, April 15, 2025 (GLOBE NEWSWIRE) -- Concept Life Sciences (CLS), a leading integrated drug discovery, development, and manufacturing organisation backed by Limerston Capital, today announced key strategic appointments and …
Cyprumed Enters License and Option Agreement with MSD for the Development of Oral Peptide Therapeutics
GlobeNewswire
·
April 15, 2025
MSD obtains a Non-Exclusive License for Cyprumed’s delivery technology to develop oral peptide therapeutics Cyprumed will be eligible to receive up to $493 million in upfront, development, regulatory and sales milestones INNSBRUCK, Austria, April 15, 2025 …
1ST Biotherapeutics Joins The Michael J. Fox Foundation’s LITE Program to Advance LRRK2-Based Parkinson’s Disease Research
GlobeNewswire
·
April 15, 2025
Focus on the discovery of next-generation LRRK2 inhibitors to unlock novel biological mechanisms of action and advance new treatment options YONGIN, South Korea, April 15, 2025 – 1ST Biotherapeutics, Inc. (1STBIO), a clinical-stage biopharmaceutical …
Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases
GlobeNewswire
·
April 15, 2025
Partnership bolsters Boehringer’s autoimmune and inflammatory disease pipeline portfolio aiming to tackle areas of high unmet patient need. The agreement focuses on further research and development of a novel, first-in-class bispecific …